Indications for Verzenio (Abemaciclib)
Verzenio is FDA-approved for adult patients with hormone receptor-positive, HER2-negative breast cancer in three distinct settings: (1) adjuvant treatment of node-positive early breast cancer at high risk of recurrence in combination with endocrine therapy, (2) initial endocrine-based therapy for advanced/metastatic disease combined with an aromatase inhibitor, and (3) treatment of advanced/metastatic disease after endocrine therapy progression, either combined with fulvestrant or as monotherapy after prior chemotherapy. 1
Early Breast Cancer (Adjuvant Setting)
For adjuvant treatment, Verzenio is indicated in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for adult patients with HR-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence. 1
High-risk criteria are defined as:
- ≥4 positive axillary lymph nodes, OR
- 1-3 positive lymph nodes PLUS at least one of:
Treatment duration is 2 years of abemaciclib at 150 mg twice daily combined with at least 5 years of endocrine therapy. 1 This recommendation is based on the monarchE trial, which demonstrated a statistically significant improvement in invasive disease-free survival (HR 0.747; 95% CI 0.598-0.932) with an absolute improvement of 5.4% at 3 years. 3 The 2024 ASCO guideline provides a strong recommendation for this indication, particularly for patients meeting the original monarchE eligibility criteria. 4
Advanced or Metastatic Breast Cancer
First-Line Treatment
Verzenio 150 mg twice daily combined with an aromatase inhibitor is indicated as initial endocrine-based therapy for HR-positive, HER2-negative advanced or metastatic breast cancer. 1 This represents standard-of-care first-line treatment based on current guidelines. 5, 6
The 2021 ESMO guideline establishes CDK4/6 inhibitors plus endocrine therapy as the preferred first-line approach for ER-positive, HER2-negative metastatic breast cancer, noting that this combination yields similar or better efficacy versus chemotherapy with less toxicity. 5 The MONARCH 3 trial demonstrated improved progression-free survival (median not reached vs 14.7 months; HR 0.54) with abemaciclib plus aromatase inhibitor compared to aromatase inhibitor alone. 6
For premenopausal women and men, concurrent treatment with a GnRH agonist is required when combining Verzenio with an aromatase inhibitor. 1
Second-Line Treatment (After Endocrine Therapy Progression)
Verzenio 150 mg twice daily combined with fulvestrant is indicated for HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy. 1 This is a Category 1 recommendation in NCCN guidelines. 7
Premenopausal or perimenopausal women must receive concurrent GnRH agonist therapy when combining Verzenio with fulvestrant. 1
Monotherapy (Third-Line and Beyond)
Verzenio 200 mg twice daily as monotherapy is indicated for HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy AND prior chemotherapy in the metastatic setting. 1
This distinguishes abemaciclib from palbociclib and ribociclib, which have not demonstrated single-agent efficacy and must be combined with endocrine therapy. 5 The monotherapy indication provides an option for heavily pretreated patients, though combination therapy remains preferred when feasible.
Key Clinical Considerations
Abemaciclib should be prioritized in patients with visceral crisis or rapidly progressive disease requiring urgent response, as it has demonstrated limited single-agent activity unlike other CDK4/6 inhibitors. 5 However, chemotherapy remains appropriate for immediately life-threatening disease where time to response is critical. 8
The most common dose-limiting toxicity is diarrhea (grade 3/4 in approximately 10% of patients), which typically requires proactive management with antidiarrheals and dose modifications. 9, 3 Neutropenia occurs frequently but febrile neutropenia remains rare (<1%). 6, 9
Treatment should continue until disease progression, unacceptable toxicity, or completion of 2 years in the adjuvant setting. 1 For patients unable to tolerate 50 mg twice daily after dose reductions, discontinuation is recommended. 1